JSC Biocad has been given a significant contract by Moscow's State Budgetary Healthcare Institution, "City Clinical Hospital named after S.S. Yudin," to supply the drug bevacizumab through 2026. The hospital's oncology treatment programmes will be supported by the ₽184,053,847.80 single-supplier contract, which was signed on November 26, 2025, and will last until January 20, 2027.
Details of the Contract
Clause 48 of Part 1 of Article 93 of Law No. 44-FZ, which permits procurement from a single supplier due to specialised production requirements and regulated pricing, was used to execute the contract (No. 1/26-Biocad). Important contract information consists of:-
₽184,053,847.80 is the contract price.
-
The Russian Ruble (₽) is the currency.
-
Start of Execution: November 26, 2025
-
Date of Completion: January 20, 2027
-
Delivery Address: Akademika Millionshchikova Street, 1, Nagatino-Sadovniki Municipal District, Moscow, Russia
-
Banking Assistance: Not necessary
-
Penalties: The contract stipulates that fines for unmet obligations will be deducted.
Organisations Involved
-
Client: Moscow's "City Clinical Hospital named after S.S. Yudin", a state-funded medical facility
-
Provider: JSC Biocad (INN: 5024048000, St. Petersburg)
-
Address: Svyaz Street, house 38, block 1, premises 89, Strelna settlement
-
Contact: +7 (495) 992-66-28 | bykova_y@biocad.ru
-
Bevacizumab, a targeted therapy commonly used in oncology, is supplied by JSC Biocad, a prominent Russian biopharmaceutical company, guaranteeing continuity of care for patients at one of Moscow's top clinical hospitals.
Importance of the Agreement
A monoclonal antibody called bevacizumab is essential for the treatment of several cancers, such as renal cell carcinoma, lung cancer, and colorectal cancer. By obtaining this contract, the hospital strengthens Moscow's public healthcare system's ability to provide cutting-edge oncology care by guaranteeing continuous access to life-saving treatments.The specialised nature of the medication and the need to uphold controlled pricing and production standards in compliance with Russian law are reflected in the single-supplier procurement.
Background on JSC Biocad
A well-known biopharmaceutical business in Russia, JSC Biocad specialises in the creation, manufacturing, and distribution of cutting-edge medications, such as monoclonal antibodies and cancer treatments. The company has a long history of providing vital pharmaceutical products to public health organisations and government hospitals.In conclusion
The agreement between JSC Biocad and Moscow's City Clinical Hospital ensures that bevacizumab will be available through January 2027 to support ongoing cancer treatment initiatives. This agreement guarantees Moscow patients' continuous access to necessary medications as well as regulatory compliance.RussiaTenders: Russia's Most Recent Government Contract Awards and Tenders
- RussiaTenders is your reliable resource for the most recent Russian contract awards, RFPs, RFQs, and government tenders
- Visit RussiaTenders to stay informed about the most recent public procurement opportunities and tender notices in Russia
- RussiaTenders has all of the Russian government's contract award notices, eProcurement updates, and tenders
- Use RussiaTenders, the RussiaTenders portal, to investigate current bids, tenders, and procurement opportunities in Russia
- RussiaTenders provides you with contract awards, procurement news, and verified tenders from Russia
#Moscow #CityClinicalHospital #Bevacizumab #JSCBiocad #ContractAward #TenderResults #PharmaceuticalSupply #OncologyTreatment #GovernmentProcurement #RussianHealthcare
